Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

Illinois has confirmed its first human case of West Nile virus this year, health officials say. The person, who lives in ...

A new study says common human typing errors can trip up artificial intelligence (AI) programs designed to aid health care ...

The Investment Committee discuss their strategy on some stocks on the move today. Mexico President Claudia Sheinbaum tells ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Investing.com -- Hims & Hers Health (NYSE: HIMS) has named Dheerja Kaur as its first-ever Chief Product Officer, according to an announcement from CEO Andrew Dudum.